Atara Biotherapeutics (ATRA) Research & Development (2013 - 2026)
Atara Biotherapeutics (ATRA) posted Research & Development of $164000.0 for Q1 2026, up 173.54% on a QoQ basis from -$223000.0 in Q4 2025, and down 99.4% year-over-year from $27.4 million in Q1 2025.
Atara Biotherapeutics (ATRA) Research & Development (2013 - 2026) Analysis & Trends
Atara Biotherapeutics' Research & Development history runs 14 years deep, the most recent figure standing at $164000.0 for Q1 2026.
- Quarterly Research & Development fell 99.4% year-over-year to $164000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (down 92.37% YoY) and the FY2025 annual result came in at $37.4 million, down 75.28% from the prior year.
- Research & Development was $164000.0 for Q1 2026 at Atara Biotherapeutics, up from -$223000.0 in the prior quarter.
- Across five years, Research & Development topped out at $75.0 million in Q1 2022 and bottomed at -$223000.0 in Q4 2025.
- A 5-year average of $40.4 million and a median of $45.5 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development gained 17.02% — and 2025, when it slumped 100.78%.
- Atara Biotherapeutics' Research & Development stood at $62.5 million in 2022, then fell by 20.66% to $49.6 million in 2023, then sank by 42.09% to $28.7 million in 2024, then slumped by 100.78% to -$223000.0 in 2025, then jumped by 173.54% to $164000.0 in 2026.
- Business Quant data shows ATRA's Research & Development at $164000.0 in Q1 2026, -$223000.0 in Q4 2025, and $2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 343.97 Mn |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | 164,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 164,000.00 |
| Dec 31, 2025 | -223,000.00 |
| Sep 30, 2025 | 2.93 Mn |
| Jun 30, 2025 | 7.31 Mn |
| Mar 31, 2025 | 27.43 Mn |
| Dec 31, 2024 | 28.72 Mn |
| Sep 30, 2024 | 43.92 Mn |
| Jun 30, 2024 | 33.33 Mn |
| Mar 31, 2024 | 45.51 Mn |
| Dec 31, 2023 | 49.60 Mn |
| Sep 30, 2023 | 56.89 Mn |
| Jun 30, 2023 | 56.14 Mn |
| Mar 31, 2023 | 62.16 Mn |
| Dec 31, 2022 | 62.52 Mn |
| Sep 30, 2022 | 70.16 Mn |
| Jun 30, 2022 | 64.90 Mn |
| Mar 31, 2022 | 74.96 Mn |
| Dec 31, 2021 | 79.13 Mn |
| Sep 30, 2021 | 70.33 Mn |
| Jun 30, 2021 | 68.48 Mn |